Lorin K. Roskos - Integrated Bioanal Clin Pharmacol & Safety Sci, R&D, AstraZeneca

基本信息

浏览量：85

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 218 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Investigations of Enteric-Coated Propyl Gallate-induced Nephrotoxicity in Beagles and Human and Dog Renal Proximal Tubule Epithelial Cells

Si Mou, Brian Timothy Hummer,Jiaqi Yuan,Yue Huang,Meina Liang,Raffaella Faggioni,Lorin K. Roskos,Anton I. Rosenbaum

crossref（2024）

引用0浏览0引用

Comparison of Sequential and Joint Nonlinear Mixed Effects Modeling of Tumor Kinetics and Survival Following Durvalumab Treatment in Patients with Metastatic Urothelial Carcinoma

Chen Ting,Zheng Yanan,Roskos Lorin,Mager Donald E.

Journal of Pharmacokinetics and Pharmacodynamicsno. 4 (2023): 251-265

引用4浏览0WOS引用

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

Yue Huang,Jiaqi Yuan,Ruipeng Mu,Robert J. Kubiak,Kathryn Ball,Mingyan Cao,G. Patrick Hussmann,Niluka de Mel,Dengfeng Liu,Lorin K. Roskos,Meina Liang,Anton I. Rosenbaum

ANTIBODIESno. 4 (2023)

引用0浏览0WOS引用

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

Neang S. Ly, Jing Li,Raffaella Faggioni,Lorin K. Roskos,Marcia S. Brose

Clinical Pharmacokinetics（2023）

引用0浏览0WOS引用

Combining Pharmacometric Models with Predictive and Prognostic Biomarkers for Precision Therapy in Crohn's Disease: A Case Study of Brazikumab

Nan Zhang, Ming Liang Chan, Jing Li,Philip Z. Brohawn, Bo Sun,Inna Vainshtein,Lorin K. Roskos,Raffaella Faggioni,Rada M. Savic

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYno. 12 (2023): 1945-1959

引用3浏览0WOS引用

Cabozantinib Exposure–response Analysis for the Phase 3 CheckMate 9ER Trial of Nivolumab Plus Cabozantinib Versus Sunitinib in First-Line Advanced Renal Cell Carcinoma

Benjamin Duy Tran, Jing Li,Neang Ly,Raffaella Faggioni,Lorin Roskos

Cancer Chemotherapy and Pharmacology（2023）

引用6浏览0WOS引用

Mechanistic Modeling of a Human IgG4 Monoclonal Antibody (tralokinumab) Fab‐arm Exchange with Endogenous IgG4 in Healthy Volunteers

Bing Wang, Jo Goodman,Lorin K. Roskos

CPT Pharmacometrics & Systems Pharmacology（2022）

引用1浏览0WOS引用

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients with Systemic Lupus Erythematosus

Joachim Almquist,Denison Kuruvilla,Tu Mai,Raj Tummala,Wendy White,Weifeng Tang,Lorin Roskos,Yen Lin Chia

The Journal of Clinical Pharmacology（2022）

引用6浏览0WOS引用

P48.21 Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

Y. Zheng,D. Jin, Y. Guan,M. Ozguroglu,D. Trukhin,A. Poltoratskiy,Y. Chen,L. Havel,M. Hochmair,L. Paz-Ares,H. Jiang,J. Armstrong,C. Chen, Y. H. Liu,L. Roskos

Journal of Thoracic Oncology（2021）

引用2浏览0引用

Association of Circulating Protein Biomarkers with Clinical Outcomes of Durvalumab in Head and Neck Squamous Cell Carcinoma

Rosalinda Arends,Xiang Guo,Paul G. Baverel,Ignacio Gonzalez-Garcia, James Xie,Nassim Morsli,Alejandro Yovine,Lorin K. Roskos

OncoImmunology（2021）

引用9浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn